Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by Addex Therapeutics Ltd. for the month of June 2025. The filing, dated June 25, 2025, serves primarily to incorporate by reference a press release issued on the same date (Exhibit 99.1). The registrant is based in Geneva, Switzerland, and files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a conduit for a press release rather than a financial statement containing quantitative data.
Material Changes
No material financial changes versus prior periods are detailed in the text of this filing. The document references the issuance of a press release but does not summarize its content or disclose specific operational or financial shifts within the body of the Form 6-K.
Guidance, Outlook, and Risks
The filing does not contain management commentary, guidance, outlook, or a discussion of risks and contingencies. These details are presumed to be contained within the attached press release (Exhibit 99.1), which is incorporated by reference into the company's registration statements on Form F-3 and Form S-8.
Key Facts for Investor Verification
- Review the attached press release (Exhibit 99.1) for the specific announcement made on June 25, 2025, as the Form 6-K body contains no substantive details.
- Verify the impact of the press release announcement on the company's registration statements (Form F-3 No. 333-255089 and Form S-8 Nos. 333-255124 and 333-272515).
- Note that no financial metrics are disclosed in this specific filing; investors must refer to the most recent Form 20-F or quarterly reports for financial data.